What is Metastatic Breast Cancer?

Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs, most commonly to the bones, lungs, liver, or brain. Unlike early-stage breast cancer that remains within the breast tissue or nearby lymph nodes, MBC has traveled through the bloodstream or lymphatic system to establish new tumors elsewhere in the body.

While MBC is considered incurable with current medical knowledge, it is treatable, and many patients live for years with good quality of life. The primary goal of treatment shifts from eliminating the cancer completely to controlling its spread, managing symptoms, and maintaining quality of life for as long as possible. Each patient's treatment plan is individualized based on multiple factors, including the specific characteristics of their cancer, previous treatments, overall health status, and personal preferences.

Hormonal Therapy Approaches

Hormonal therapy (also called endocrine therapy) is often the first treatment approach for hormone receptor-positive MBC. This type of breast cancer, which accounts for approximately 70% of all cases, has cells that grow in response to estrogen or progesterone.

Several classes of hormonal therapies exist, each working differently to prevent hormones from fueling cancer growth. Selective estrogen receptor modulators (SERMs) like tamoxifen block estrogen receptors on cancer cells. Aromatase inhibitors such as anastrozole, letrozole, and exemestane reduce estrogen production in postmenopausal women. Selective estrogen receptor degraders (SERDs) like fulvestrant destroy estrogen receptors.

Recent advances have led to the development of CDK4/6 inhibitors, which, when combined with hormonal therapy, have shown significant improvements in progression-free survival. These medications include palbociclib, ribociclib, and abemaciclib, which work by blocking proteins that help cancer cells divide and grow.

Targeted Therapy Options

Targeted therapies focus on specific molecular features of cancer cells. For MBC patients whose tumors overexpress the HER2 protein (HER2-positive), anti-HER2 targeted therapies have revolutionized treatment outcomes.

HER2-targeted agents include monoclonal antibodies like trastuzumab and pertuzumab that bind to HER2 receptors, preventing growth signals. Antibody-drug conjugates such as Seagen's trastuzumab deruxtecan and Gilead's sacituzumab govitecan deliver chemotherapy directly to cancer cells. Small molecule inhibitors like tucatinib block HER2 signaling from within the cell.

For patients with PIK3CA mutations, Novartis developed alpelisib, which targets a specific protein in the PI3K pathway. PARP inhibitors such as olaparib and talazoparib benefit patients with BRCA mutations by preventing cancer cells from repairing their damaged DNA. Immunotherapy approaches using checkpoint inhibitors like pembrolizumab are showing promise for triple-negative breast cancer, which lacks hormone receptors and HER2 expression.

Chemotherapy Regimens

Chemotherapy remains a cornerstone treatment for many MBC patients, particularly those with hormone receptor-negative disease, rapidly progressing cancer, or visceral crisis (severe organ dysfunction). These powerful medications work by killing fast-dividing cells throughout the body.

Common chemotherapy agents used for MBC include taxanes (paclitaxel, docetaxel), anthracyclines (doxorubicin, epirubicin), capecitabine, gemcitabine, vinorelbine, and platinum compounds (carboplatin, cisplatin). Unlike early-stage breast cancer treatment, chemotherapy for MBC is typically administered sequentially (one drug at a time) rather than in combination, to minimize side effects while maintaining efficacy.

Pfizer and Merck are among the pharmaceutical companies developing innovative chemotherapy approaches for MBC. Treatment schedules vary widely, with some regimens given weekly, others every three weeks, and some in oral form daily. The choice of agent and schedule depends on the cancer's characteristics, previous treatments, the patient's overall health, and quality of life considerations.

Radiation and Surgery Considerations

While systemic therapies form the backbone of MBC treatment, localized approaches like radiation therapy and surgery play important supportive roles in specific situations. Radiation therapy uses high-energy beams to target cancer cells in specific areas and is particularly valuable for managing painful bone metastases, brain metastases, or other localized symptoms.

Stereotactic body radiation therapy (SBRT) delivered by equipment from companies like Varian allows precise, high-dose radiation to be delivered to small metastatic tumors while sparing surrounding healthy tissue. This approach, sometimes called stereotactic ablative radiotherapy, may be used for limited metastatic disease.

Surgery in MBC is generally reserved for palliative purposes—relieving symptoms or preventing complications rather than curing the disease. Examples include stabilizing a bone at risk of fracture, removing a painful lesion, or addressing brain metastases causing neurological symptoms. In highly selected cases with limited metastatic disease (oligometastasis), surgery to remove isolated metastases may be considered as part of a comprehensive treatment approach.

Conclusion

Treatment for metastatic breast cancer continues to evolve rapidly, with promising new therapies emerging from ongoing clinical trials. The most effective approach typically involves a multidisciplinary team of specialists working together to create personalized treatment plans. While MBC remains incurable, advances in treatment have helped many patients live longer with better quality of life. Patients should discuss all available options with their healthcare team, including clinical trials through organizations like BreastCancerTrials.org, to determine the most appropriate treatment strategy for their specific situation. Support resources from groups such as Metastatic Breast Cancer Alliance can provide valuable information and community throughout the treatment journey.

Citations

This content was written by AI and reviewed by a human for quality and compliance.